-
公开(公告)号：US10451634B2
公开(公告)日：2019-10-22
申请号：US15720073
申请日：2017-09-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Murli Krishna , Alexander T. Kozhich , Martin J. Corbett , Zheng Lin , Steven P. Piccoli
Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
-
公开(公告)号：US10406212B2
公开(公告)日：2019-09-10
申请号：US15491271
申请日：2017-04-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Alexander T. Kozhich , Martin J. Corbett
IPC: C07K14/00 , A61K38/39 , C07K14/78 , C07K16/46 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K47/60 , A61K38/00
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20180038872A1
公开(公告)日：2018-02-08
申请号：US15720073
申请日：2017-09-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Murli Krishna , Alexander T. Kozhich , Martin J. Corbett , Zheng Lin , Steven P. Piccoli
CPC classification number: G01N33/6854 , C07K16/44 , C07K2317/24 , C07K2317/33 , C07K2317/92 , G01N2800/52
Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
-
公开(公告)号：US10245302B2
公开(公告)日：2019-04-02
申请号：US15282277
申请日：2016-09-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: C12P21/02 , C07K14/78 , A61K38/39 , C07K16/46 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K47/60 , A61K47/48 , A61K38/00
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20190062456A1
公开(公告)日：2019-02-28
申请号：US16117183
申请日：2018-08-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , G01N33/573 , A61K45/06 , C07K16/28 , C07K16/30 , A61K39/395 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
Patent Agency Ranking
公开(公告)号：US20160231328A1
公开(公告)日：2016-08-11
申请号：US15018353
申请日：2016-02-08
Applicant: Bristol-Myers Squibb Company
Inventor： Murli KRISHNA , Alexander T. Kozhich , Martin J. Corbett , Zheng Lin , Steven P. Piccoli
CPC classification number: G01N33/6854 , C07K16/44 , C07K2317/24 , G01N2800/52
Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
Abstract translation: 聚乙二醇（PEG）通常与治疗性蛋白质结合以增强其PK性质。 然而，PEG可能是免疫原性的，并且据信PEG在食品和化妆品中的存在导致人中预先存在的抗-PEG抗体。 提供与PEG反应的多克隆和单克隆抗体用于免疫原性测定开发以检测此类抗药物抗体。 此类抗体基于分子量范围为350道尔顿至40kD的PEG的大小显示优先结合。 将本发明的抗-PEG抗体工程改造成包含人Fc区域以实现非桥接免疫测定形式。
-
公开(公告)号：US11813315B2
公开(公告)日：2023-11-14
申请号：US16276156
申请日：2019-02-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/39 , C07K14/78 , C07K16/46 , A61K45/06 , G01N33/74 , A61K47/60 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K38/00
CPC classification number: A61K38/39 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , G01N33/74 , A61K38/00 , C07K2319/30 , C07K2319/31
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20230051701A1
公开(公告)日：2023-02-16
申请号：US17737403
申请日：2022-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , C07K16/28 , C07K16/30 , A61K39/395 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US08933199B2
公开(公告)日：2015-01-13
申请号：US14025253
申请日：2013-09-12
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Martin J. Corbett , Alexander T. Kozhich
IPC: C07K14/00 , C07K16/00 , C07K14/78 , C07K16/46 , A61K38/39 , A61K47/48 , A61K45/06 , G01N33/74 , C07K14/435
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
10.发明申请FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN 有权基于FIBRONECTIN的SCAFFOLD域蛋白质与MYOSTATIN相结合公开(公告)号：US20140309163A1
公开(公告)日：2014-10-16
申请号：US14275542
申请日：2014-05-12
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon CLOAD , Linda ENGLE , Dasa LIPOVSEK , Malavi MADIREDDI , Ginger Chao RAKESTRAW , Joanna SWAIN , Wenjun ZHAO , Martin J. Corbett , Alexander T. Kozhich
IPC: C07K14/78 , C07K14/79 , C07K14/765 , C07K16/18
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Abstract translation: 本发明涉及结合肌生成抑制素的基于纤连蛋白的支架结构域蛋白。 本发明还涉及这些蛋白质用于治疗肌营养不良症，恶病质，肌肉减少症，骨关节炎，骨质疏松症，糖尿病，肥胖症，COPD，慢性肾脏疾病，心力衰竭，心肌梗死和纤维化的治疗应用中的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码蛋白质的多核苷酸的载体。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.029 seconds)
